Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India
· Delayed Price · Currency is INR | Market Cap | 937.26B |
| Revenue (ttm) | 244.94B |
| Net Income (ttm) | 49.20B |
| Shares Out | 1.01B |
| EPS (ttm) | 48.89 |
| PE Ratio | 19.05 |
| Forward PE | 21.53 |
| Dividend | 11.00 (1.18%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 892,186 |
| Average Volume | 1,038,588 |
| Open | 936.00 |
| Previous Close | 935.75 |
| Day's Range | 929.25 - 937.00 |
| 52-Week Range | 795.00 - 1,059.05 |
| Beta | 0.43 |
| RSI | 40.18 |
| Earnings Date | Feb 14, 2026 |
About Zydus Lifesciences
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi... [Read more]
Financial Performance
In 2024, Zydus Lifesciences's revenue was 232.42 billion, an increase of 18.90% compared to the previous year's 195.47 billion. Earnings were 45.26 billion, an increase of 17.26%.
Financial StatementsNews
Zydus Lifesciences receives EIR from USFDA for the injectable facility at Jarod
Zydus Lifesciences has shared an important regulatory update that signals steady progress at one of its key manufacturing sites. The...
Top stocks to watch today, November 28: Adani Enterprises, Wipro, TCS, Tata Technologies, Zydus Lifesciences and more
Indian markets are expected to see stock-specific movement today as several companies released fresh business updates, regulatory filings, and expansion...
Zydus Lifesciences gets USFDA Tentative nod for Empagliflozin and Linagliptin tablets
Zydus Lifesciences Limited has secured a tentative approval from the United States Food and Drug Administration (USFDA) for its Empagliflozin...
Zydus Lifesciences signs exclusive licensing agreement with RK Pharma for novel oncology supportive care injectable
Zydus Lifesciences Ltd., the global healthcare group known for its focus on innovation-driven therapies, has announced a significant step forward...
Top stocks to watch today, November 26: NCC, Zydus Lifesciences, UBL, Waaree Energies, NELCO and more
The global market sentiment, along with early trends from GIFT Nifty, suggests that Indian equity indices are likely to open...
Top stocks to watch on November 26, 2025: NCC, Zen Technologies, Zydus Lifesciences, Bharti Airtel, HCL Tech, ACS Technologies in focus today
Indian stock market will see action across multiple sectors on Wednesday, with defence contractors, infrastructure majors, pharmaceutical companies and FMCG...
Zydus Lifesciences secures USFDA approval for Leuprolide Acetate Injection
Zydus Lifesciences has strengthened its US oncology portfolio with a fresh approval from the United States Food and Drug Administration...
Zydus Lifesciences receives USFDA tentative approval for Diroximel Fumarate capsule, 231 mg
Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for its Diroximel Fumarate...
Zydus Lifesciences’ robotic surgical system ‘Andy’ secures CE mark approval
Zydus Lifesciences Ltd. announced a significant regulatory milestone as Amplitude Surgical, a wholly owned subsidiary of Zydus MedTech France SAS,...
Zydus Lifesciences secures first-ever approval from China’s NMPA for Venlafaxine ER Capsules
Zydus Lifesciences Limited has achieved a major milestone with its first-ever approval from the National Medical Products Administration (NMPA), China....
Zydus Lifesciences Ltd (BOM:532321) Q2 2026 Earnings Call Highlights: Robust Revenue Growth ...
Zydus Lifesciences Ltd (BOM:532321) Q2 2026 Earnings Call Highlights: Robust Revenue Growth Amidst Rising Expenses
Q2 2026 Zydus Lifesciences Ltd Earnings Call Transcript
Q2 2026 Zydus Lifesciences Ltd Earnings Call Transcript
Zydus Lifesciences receives USFDA Orphan Drug Designation for Desidustat to treat beta-thalassemia
Zydus Lifesciences Ltd, a leading global discovery-based pharmaceutical company, announced that the US Food and Drug Administration (USFDA) has granted...
Zydus Lifesciences receives ‘No Action Indicated’ classification from USFDA for Ahmedabad SEZ-II facility
Zydus Lifesciences Limited announced that the U.S. Food and Drug Administration (USFDA) has successfully completed a Pre-Approval Inspection (PAI) at...
Zydus Lifesciences receives GST demand order worth Rs 74.23 crore; to challenge ruling
Zydus Lifesciences has announced that it received a demand Order-In-Original from the Joint Commissioner of Common Adjudication Authority, CGST, Ahmedabad,...
Zydus and Lupin shares in focus today after Astellas raises Mirabegron guidance by 80%
Shares of Zydus Lifesciences and Lupin are likely to stay in focus after a key development around Mirabegron, a drug...
Zydus Lifesciences receives Health Canada approval for Liothyronine tablets 5 mcg and 25 mcg
Zydus Lifesciences Limited, including its subsidiaries and affiliates (“Zydus”), has received a Notice of Compliance (NOC) from Health Canada for...
Zydus Lifesciences gets USFDA nod for Deflazacort oral suspension
Zydus Lifesciences Ltd on Monday announced that it has received final approval from the United States Food and Drug Administration...
Zydus Lifesciences extends closing date for acquisition of Sterling Biotech’s API business
Zydus Lifesciences Limited has announced an extension in the timeline for its proposed acquisition of the API (Active Pharmaceutical Ingredients) business of Sterling Biotech Limited (SBL). The compan...
Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street
Pharmaceutical stocks, particularly Indian firms, plummeted following President Trump's announcement of 100% tariffs on imported branded medicines to the US. Companies like Sun Pharma, Biocon, and Zyd...
Zydus Lifesciences shares slip nearly 3% as Trump’s pharma tariff rattles sector
Shares of Zydus Lifesciences fell 2.26% to ₹996.20 on Friday, edging closer to a 3% drop, as Indian pharmaceutical counters came under heavy selling pressure after U.S. President Donald Trump announce...
Zydus Lifesciences’ ZyVet launches first veterinary-approved generic of Furosemide tablets
Zydus Lifesciences Ltd., a global healthcare company known for its innovation-led approach, has announced a major milestone in veterinary medicine through its U.S. subsidiary. ZyVet®, the dedicated an...
Zydus Lifesciences’ ZyVet launches first FDA-approved generic treatment for canine urinary incontinence
ZyVet® Animal Health, the animal health division of Zydus Lifesciences, has launched its first FDA-approved generic version of phenylpropanolamine hydrochloride tablets, a trusted treatment for managi...
Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
New York, USA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Basal Cell N...
Zydus Lifesciences shares jump over 2% as subsidiary enters into licensing and supply agreement with Synthon BV
Zydus Lifesciences shares rose over 2% in early morning trade following a major announcement by the company regarding its subsidiary’s strategic move in the US pharmaceutical market. The subsidiary ha...